A Phase 3 interventional study of Follitropin delta and Placebo in Infertility, Female, sponsored by Ferring Pharmaceuticals. Completed at 24 sites in United States. Open to female participants aged 35 Years to 42 Years. Per ClinicalTrials.gov, last updated 2024-01-18.
Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Infertility, Female with a site in United States — 22 open to participants now, 25 under way, none of them phase 3. Infertility, Female · United States.
Among the 65 studies in Infertility, Female with a site in United States, this one is the 2nd largest by enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2018, is one of 3 in phase 3, and was the 21st registered.
552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.
Browse Infertility, Female studies →22 of the 65 studies in Infertility, Female with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–40 · Women only
Shady Grove Fertility Reproductive Science Center · Sites in United States
Women only
University of Southern California · Sites in United States
Ages 18–44 · Women only
University of Colorado, Denver · Sites in United States
Ages 18–38 · Women only · Healthy volunteers
Center for Reproductive Health & Gynecology · Sites in United States, Mexico
Ages 18–55 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 35 Years to 42 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4 · Phase 4 6
First in 2004; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 588 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 50 across the 47 interventional studies, 175 across the 18 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 65 have an industry lead sponsor. The 10 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
Ferring Pharmaceuticals has 9 studies filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
5 of the studies in Infertility, Female with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06434233Johns Hopkins UniversityOpioid Use After Laparoscopic Salpingectomy | 2026-11 |
| NCT05997407Virginia Polytechnic Institute and State UniversityThe Effect of a Mindset Management Approach on Stress Levels in Women With Infertility | 2026-12 |
| NCT07858435New Hope Fertility CenterIntra-ovarian CAPA-IVM vs Standard IVM | 2027-03 |
| NCT06686537University of Colorado, DenverConvergent Mechanisms Underlying Reprometabolic Syndrome in Women | 2027-10 |
| NCT04628507Genomic Prediction Inc.Cell Free Preimplantation Genetic Testing | 2027-11-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 65 studies in Infertility, Female with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial investigates the effects of FE 999049 compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Follitropin delta
Drug: Placebo
FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 15 μg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 μg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 μg, and the maximum daily dose was 24 μg. Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed
Also known as: FE 999049, REKOVELLE
Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049. Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.
Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS)
Defined as at least one intrauterine viable fetus 8-9 weeks after transfer. Data in this endpoint are presented for the fresh cycle and the cryopreserved cycles.
Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Ongoing Pregnancy Rate in the Fresh Cycle and in the Cryopreserved Cycles
Defined as at least one intrauterine viable fetus 8-9 weeks after transfer. Data in this endpoint are presented for the fresh cycle and the cryopreserved cycles.
Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Time From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Including Duration
Time from start of COS to ongoing pregnancy, including both the fresh and cryopreserved cycles. In the placebo group, no participants achieved an ongoing pregnancy either after 12 calendar months or after 12 study months.
Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Time From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Measured in Number of Cycles Before Achieving Ongoing Pregnancy
Time from start of COS to ongoing pregnancy, including both the fresh and cryopreserved cycles, measured in number of cycles before achieving ongoing pregnancy. In the placebo group, no participants achieved an ongoing pregnancy either after 12 calendar months or after 12 study months.
Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Ongoing Implantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
Defined as the number of intrauterine viable fetuses 8-9 weeks after transfer divided by number of blastocysts transferred. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles. One participant can contribute with a range from zero to multiple blastocysts. Data is not shown for placebo arm because no subjects underwent blastocyst transfer in the fresh cycle or cryopreserved cycles. '%' in the unit of measure refers to 'percentage'.
Time frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)
Clinical Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
Defined at least one gestational sac 5-6 weeks after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.
Time frame: 5-6 weeks after transfer (up to approximately 15 months after start of stimulation)
Vital Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
Defined at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.
Time frame: 5-6 weeks after transfer (up to approximately 15 months after start of stimulation)
Implantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
Defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred. The endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles. One participant can contribute with a range from zero to multiple blastocysts. Data is not shown for placebo arm because no subjects underwent blastocyst transfer in the fresh cycle or cryopreserved cycles. '%' in the unit of measure refers to 'percentage'.
Time frame: 5-6 weeks after transfer (up to approximately 15 months after start of stimulation)
Positive Beta Human Chorionic Gonadotropin (βhCG) Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively
Defined as positive serum βhCG test 10-14 days after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.
Time frame: 10-14 days after transfer (up to approximately 14 months after start of stimulation)
Proportion of Subjects in the Fresh Cycle With Triggering of Final Follicular Maturation (With hCG, With GnRH Agonist, and in Total), Cycle Cancellation and Transfer Cancellation
Data in this endpoint are presented for the fresh cycle.
Time frame: Up to 5 days after oocyte retrieval (up to 27 days after start of stimulation)
Number of Follicles on Stimulation Day 5
The total number of follicles and the number of follicles per size category are reported.
Time frame: On stimulation day 5
Number of Follicles at End-of-stimulation
The total number of follicles and the number of follicles per size category are reported.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Size of Follicles on Stimulation Day 5
Counted by ultrasound for the right and left ovary for each participant.
Time frame: On stimulation day 5
Size of Follicles at End-of-stimulation
Counted by ultrasound for the right and left ovary for each participant.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Number of Oocytes Retrieved
The number of oocytes retrieved was recorded at the oocyte retrieval visit.
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved
Grouped according to the number of oocytes retrieved. Participants with cycle cancellation due to poor ovarian response are included in the \<4 oocytes group.
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Number of Metaphase II Oocytes
The number of MII oocytes to oocytes retrieved for participants where all oocytes were inseminated using ICSI are presented.
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Number of Fertilized Oocytes
An oocyte was defined as fertilized if it had 2 pronuclei (2PN) at 19h (±2h).
Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Fertilization Rate
The fertilization rate was defined as the number of 2PN oocytes divided by the number of oocytes retrieved. Fertilization rate relative to oocytes retrieved has been reported.
Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Number and Quality of Blastocysts on Day 5 After Oocyte Retrieval
Number of blastocysts (total and good-quality) on Day 5 are presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.
Time frame: On day 5 after oocyte retrieval
Endometrial Thickness on Stimulation Day 5
Mean endometrial thickness is reported.
Time frame: On stimulation day 5
Endometrial Thickness at End-of-stimulation
Mean endometrial thickness is reported.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Echogenicity Pattern on Stimulation Day 5
The distribution of participants with hypoechogenic, isoechogenic, or hyperechogenic endometrium is reported
Time frame: On stimulation day 5
Echogenicity Pattern at End-of-stimulation
The distribution of participants with hypoechogenic, isoechogenic, or hyperechogenic endometrium is reported.
Time frame: At end-of-stimulation (up to 20 stimulation days)
Oocyte Utilization Rate
Defined as the number of blastocysts transferred or cryopreserved divided by the number of oocytes retrieved. Data in this endpoint are presented for the cryopreserved cycles.
Time frame: On day of oocyte retrieval up to 12 months after start of COS
Oocyte Efficiency Index
Defined as the cumulative number of ongoing pregnancies per oocyte retrieved. Data in this endpoint are presented for the cryopreserved cycles. The unit of measure for this endpoint is 'cumulative ongoing pregnancies/oocyte retrieved'.
Time frame: 8-9 weeks after transfer
Percentage of Blastocysts Surviving Cryopreservation
Data in this endpoint are presented for the cryopreserved cycles. The unit is number of blastocysts with observations. One participant can contribute with a range from zero to multiple blastocysts.
Time frame: 0 hour (+0.5 hour) after thawing
Percentage of Blastocysts With Re-expansion After Cryopreservation
Data in this endpoint are presented for the cryopreserved cycles. The unit is number of blastocysts with observations. One participant can contribute with a range from zero to multiple blastocysts.
Time frame: 2.5 hour (±0.5 hour) after thawing
Number of Cryopreserved Cycles Initiated Within 12 Months From the Start of COS
The total number of cryopreserved cycles initiated are reported. Data in this endpoint are presented for the cryopreserved cycles. One participant can contribute with a range from zero to multiple blastocysts.
Time frame: Up to 12 months after start of stimulation
Number of Cryopreserved Cycles With Blastocyst Transfer
The total number of cryopreserved cycles with blastocyst transfer are reported. Data in this endpoint are presented for the cryopreserved cycles. One participant can contribute with a range from zero to multiple blastocysts.
Time frame: Up to 12 months after start of stimulation
Circulating Concentrations of Anti-mullerian Hormone (AMH)
Blood samples for analysis of circulating concentrations of AMH were drawn. The median and inter-quartile range (IQR) of AMH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Follicle-stimulating Hormone (FSH)
Blood samples for analysis of circulating concentrations of FSH were drawn. The median and IQR of FSH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Luteinizing Hormone (LH)
Blood samples for analysis of circulating concentrations of LH were drawn. The median and IQR of LH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Estradiol
Blood samples for analysis of circulating concentrations of estradiol were drawn. The median and IQR of estradiol levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Progesterone
Blood samples for analysis of circulating concentrations of progesterone were drawn. The median and IQR of progesterone levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Inhibin A
Blood samples for analysis of circulating concentrations of inhibin A were drawn. The median and IQR of inhibin A levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Circulating Concentrations of Inhibin B
Blood samples for analysis of circulating concentrations of inhibin B were drawn. The median and IQR of inhibin B levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
Time frame: From screening to the day of oocyte retrieval (up to 22 days after start of stimulation)
Total Gonadotropin Dose
Calculated by start dates, end dates and daily dose of IMP.
Time frame: Up to 20 stimulation days
Number of Stimulation Days
Calculated by start dates and end dates.
Time frame: Up to 20 stimulation days
Proportion of Participants With Investigator-requested Gonadotropin Dose Adjustments
Investigator-requested decreases and increases of the gonadotropin dose.
Time frame: Stimulation Day 5
Percentage of Participants With Adverse Events (AEs)
Any AE occurring after start of IMP and before the end-of-trial visit, or a pre-treatment AE or pre-existing medical condition that worsens in intensity after start of IMP and before the end-of-trial visit was considered treatment-emergent, and is presented for this endpoint. Data in this endpoint are presented for the fresh cycle.
Time frame: From time of signing informed consent until the end-of-cycle visit in the fresh cycle (approximately 6 months)
Intensity of AEs
The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activity; moderate = event sufficient to affect usual activity (disturbing); or severe = inability to work or perform usual activities (unacceptable). Data in this endpoint are presented for the fresh cycle.
Time frame: From time of signing informed consent until the end-of-cycle visit in the fresh cycle (up to approximately 6 months)
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Albumin, Protein
Blood samples were collected for the analysis of clinical chemistry parameters including: Albumin and protein. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase and Gamma Glutamyl Transferase
Blood samples were collected for the analysis of clinical chemistry parameters including: Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase and gamma glutamyl transferase. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Bicarbonate, Blood Urea Nitrogen, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium and Sodium
Blood samples were collected for the analysis of clinical chemistry parameters including: Bicarbonate, blood urea nitrogen, calcium, chloride, cholesterol, glucose, Phosphate, Potassium and Sodium. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Direct Bilirubin, Total Bilirubin, Creatinine, Urate
Blood samples were collected for the analysis of clinical chemistry parameters including: Direct bilirubin, total bilirubin, creatinine, urate. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Circulating Levels of Clinical Chemistry Compared to Baseline: Lactate Dehydrogenase
Blood samples were collected for the analysis of clinical chemistry parameters including: Lactate dehydrogenase. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Haematology Parameters Compared to Baseline: Erythrocytes
Blood samples were collected for the analysis of haematology parameter including: Erythrocytes. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Haematology Parameters Compared to Baseline: Haemoglobin
Blood samples were collected for the analysis of haematology parameters including: Haemoglobin. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Haematology Parameters Compared to Baseline: Haematocrit
Blood samples were collected for the analysis of haematology parameter including: Haematocrit. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Volume
Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular volume. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Haematology Parameters Compared to Baseline: Leukocytes and Platelets
Blood samples were collected for the analysis of haematology parameters including: Leukocytes and platelets. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Hemoglobin
Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular haemoglobin. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Haematology Parameters Compared to Baseline: Erythrocyte Mean Corpuscular Haemoglobin Concentration
Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular haemoglobin concentration. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Changes in Haematology Parameters Compared to Baseline: Basophils/Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Monocytes/Leukocytes and Neutrophils/Leukocytes
Blood samples were collected for the analysis of haematology parameters including: Basophils/leukocytes, eosinophils/ leukocytes, lymphocytes/leukocytes, monocytes/leukocytes and neutrophils/leukocytes. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Proportion of Subjects With Markedly Abnormal Changes of Clinical Chemistry Parameters: Alanine Aminotransferase, Aspartate Aminotransferase, Bicarbonate, Calcium, Potassium
The table represents the percentage of participants in each group with normal baseline values and markedly abnormal end-of-stimulation or end-of-cycle visit values for alanine aminotransferase, aspartate aminotransferase, bicarbonate, calcium, potassium. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-cycle visit in the fresh cycle (approximately 6 months)
Proportion of Subjects With Markedly Abnormal Changes of Haematology Parameters: Leukocytes, Eosinophils/Leukocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes
The table represents the percentage of participants in each group with normal baseline values and markedly abnormal end-of-stimulation or end-of-cycle visit values for Leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes and neutrophils/leukocytes. Data in this endpoint are presented for the fresh cycle.
Time frame: From screening (baseline) to the end-of-stimulation visit and end-of-cycle visit in the fresh cycle (approximately 6 months)
Frequency and Intensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period
Assessed by the participant during the stimulation period. Participants assessed the injection site reactions (redness, pain, itching, swelling and bruising) three times daily: immediately after the injection, 30 minutes after the injection and 24 hours after the injection.
Time frame: End-of-stimulation (up to 20 stimulation days)
Intensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period
Assessed by the participant during the stimulation period as mild, moderate or severe.
Time frame: End-of-stimulation (up to 20 stimulation days)
Proportion of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralizing Capacity
Measured by presence of anti-FSH antibodies. 95% Clopper-Pearson confidence interval has been reported in this endpoint.
Time frame: Up to 28 days after end of the stimulation period
Frequency and Intensity of Immune-related Adverse Events
Standardised Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs).
Time frame: From time of signing informed consent for participation in the trial until the end-of-cycle visit in the fresh cycle (approximately 6 months)
Proportion of Subjects With Cycle Cancellations Due to an Adverse Event, Including Immune-related Adverse Events, or Due to Technical Malfunctions of the Administration Pen
For each participant the reason for cycle cancellation will be recorded. Data in this endpoint are presented for the fresh cycle.
Time frame: Up to 20 stimulation days
Proportion of Subjects With OHSS, Overall and by Grade, and Proportion of Subjects With Moderate/Severe OHSS
Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe. Data in this endpoint are presented for the fresh cycle.
Time frame: ≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS)
Proportion of Subjects Hospitalized Due to OHSS and Proportion of Subjects Undergoing Paracentesis Due to OHSS
Percentage of participants hospitalized or undergoing paracentesis due to OHSS are reported
Time frame: ≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS)
Proportion of Participants With Multi-fetal Gestation in the Fresh Cycle
Defined as pregnancy with more than one fetus. Among participants with ongoing pregnancy, percentage of participants with twin pregnancies are presented. '%' in the unit of measure refers to 'percentage'.
Time frame: Up to 8-9 weeks after transfer
Proportion of Cryopreserved Cycles With Multi-fetal Gestation
Defined as pregnancy with more than one fetus. Among cryopreserved cycles with ongoing pregnancy, percentage of cycles with twin pregnancies are presented. '%' in the unit of measure refers to 'percentage'.
Time frame: Up to 8-9 weeks after transfer
Biochemical Pregnancy, Spontaneous Abortion, Ectopic Pregnancy (With and Without Medical/Surgical Intervention) and Vanishing Twins in the Fresh Cycle
The percentage of participants with biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins in the fresh cycle are presented. Data represents participants with positive βhCG. Data is not shown for placebo arm because no participants had a positive βhCG. '%' in the unit of measure refers to 'percentage'. Unit: % of participants with early pregnancy loss.
Time frame: Up to 8-9 weeks after transfer
Biochemical Pregnancy, Spontaneous Abortion, Ectopic Pregnancy (With and Without Medical/Surgical Intervention) and Vanishing Twins in the Cryopreserved Cycles
The percentage of cryopreserved cycles with biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins are presented. Data is not shown for placebo arm because no participants had a positive βhCG. '%' in the unit of measure refers to 'percentage'.
Time frame: Up to 8-9 weeks after transfer
Proportion of Participants With Technical Malfunctions of the Administration Pen
Incidences of technical malfunctions of the administration pen were recorded.
Time frame: Up to 20 stimulation days
The trial was performed in 24 investigational sites in 18 states of the United States between Oct 2018 to Dec 2020.
| Milestone | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Started | 534 | 54 |
| Modified intention-to-treat (mitt) | 533 | 54 |
| Completed | 502 | 54 |
| Not completed | 32 | 0 |
| Withdrew: Protocol deviation | 23 | 0 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Randomization failure | 1 | 0 |
| Withdrew: Participant relocated, unable to continue in trial | 1 | 0 |
| Withdrew: Participant did not show to visit (stimulation day 12) | 1 | 0 |
Defined as at least one intrauterine viable fetus 8-9 weeks after transfer. Data in this endpoint are presented for the fresh cycle and the cryopreserved cycles.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS) | 43.3 | 0.0 |
Defined as at least one intrauterine viable fetus 8-9 weeks after transfer. Data in this endpoint are presented for the fresh cycle and the cryopreserved cycles.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Fresh cycle | 22.0 | 0.0 |
| Cryopreserved cycles | 47.8 | 0 |
Time from start of COS to ongoing pregnancy, including both the fresh and cryopreserved cycles. In the placebo group, no participants achieved an ongoing pregnancy either after 12 calendar months or after 12 study months.
| days | FE 999049 (Follitropin Delta) |
|---|---|
| Total number of days until ongoing pregnancy 12 study months | 134.7 ± 87.2 |
| Total number of days until ongoing pregnancy 12 calendar months | 130.1 ± 77.8 |
Time from start of COS to ongoing pregnancy, including both the fresh and cryopreserved cycles, measured in number of cycles before achieving ongoing pregnancy. In the placebo group, no participants achieved an ongoing pregnancy either after 12 calendar months or after 12 study months.
| Cycles | FE 999049 (Follitropin Delta) |
|---|---|
| Number of cycles until ongoing pregnancy 12 study months | 1.8 ± 1.0 |
| Number of cycles until ongoing pregnancy 12 calendar months | 1.7 ± 1.0 |
Defined as the number of intrauterine viable fetuses 8-9 weeks after transfer divided by number of blastocysts transferred. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles. One participant can contribute with a range from zero to multiple blastocysts. Data is not shown for placebo arm because no subjects underwent blastocyst transfer in the fresh cycle or cryopreserved cycles. '%' in the unit of measure refers to 'percentage'.
| % of viable fetus/blastocyst transfer | FE 999049 (Follitropin Delta) |
|---|---|
| Fresh cycle | 32.7 |
| Cryopreserved cycles | 30.6 |
| All cycles | 31.6 |
Defined at least one gestational sac 5-6 weeks after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Fresh cycle | 26.8 | 0.0 |
| Cryopreserved cycles | 58.0 | 0 |
| All cycles | 52.0 | 0.0 |
Defined at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Fresh cycle | 23.5 | 0.0 |
| Cryopreserved cycles | 49.4 | 0 |
| All cycles | 45.6 | 0.0 |
Defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred. The endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles. One participant can contribute with a range from zero to multiple blastocysts. Data is not shown for placebo arm because no subjects underwent blastocyst transfer in the fresh cycle or cryopreserved cycles. '%' in the unit of measure refers to 'percentage'.
| % gestational sacs/blastocyst transfer | FE 999049 (Follitropin Delta) |
|---|---|
| Fresh cycle | 40.4 |
| Cryopreserved cycles | 40.2 |
| All cycles | 40.3 |
Defined as positive serum βhCG test 10-14 days after transfer. Data in this endpoint are presented for the fresh cycle, the cryopreserved cycles, and all cycles.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Fresh cycle | 32.1 | 0.0 |
| Cryopreserved cycles | 65.3 | 0 |
| All cycles | 58.9 | 0.0 |
Data in this endpoint are presented for the fresh cycle.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Triggering drug (hCG) | 79.5 | 1.9 |
| Triggering drug (GnRH agonist) | 15.0 | 0.0 |
| Triggering drug (None) | 5.4 | 98.1 |
| Cycle cancellation | 5.4 | 98.1 |
| Transfer cancellation | 31.5 | 1.9 |
The total number of follicles and the number of follicles per size category are reported.
| number of follicles | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Total number of follicles | 14.8 ± 8.4 | 12.5 ± 8.0 |
| Follicles >= 12 mm | 1.7 ± 1.8 | 0.4 ± 0.6 |
| Follicles >= 17 mm | 0.0 ± 0.2 | 0.0 ± 0.2 |
The total number of follicles and the number of follicles per size category are reported.
| number of follicles | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Total number of follicles | 17.4 ± 10.0 | 13.6 ± 9.5 |
| Follicles >= 12 mm | 10.1 ± 6.3 | 0.8 ± 0.7 |
| Follicles >= 17 mm | 3.6 ± 2.3 | 0.4 ± 0.5 |
Counted by ultrasound for the right and left ovary for each participant.
| mm | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Largest follicle (mm) | 12.4 ± 2.3 | 10.8 ± 2.5 |
| Average size of 2 largest follicles (mm) | 11.8 ± 2.1 | 9.8 ± 1.9 |
Counted by ultrasound for the right and left ovary for each participant.
| mm | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Largest follicle (mm) | 19.8 ± 2.7 | 14.1 ± 5.1 |
| Average size of 2 largest follicles (mm) | 18.9 ± 2.6 | 11.5 ± 3.3 |
The number of oocytes retrieved was recorded at the oocyte retrieval visit.
| number of oocytes retrieved | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Number of Oocytes Retrieved | 11.3 ± 8.9 | 0.0 ± 0.1 |
Grouped according to the number of oocytes retrieved. Participants with cycle cancellation due to poor ovarian response are included in the \<4 oocytes group.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| <4 oocytes retrieved | 14.6 | 100 |
| 4-7 oocytes retrieved | 23.5 | 0 |
| 8-14 oocytes retrieved | 33.8 | 0 |
| 15-19 oocytes retrieved | 15.2 | 0 |
| >=20 oocytes retrieved | 12.9 | 0 |
The number of MII oocytes to oocytes retrieved for participants where all oocytes were inseminated using ICSI are presented.
| number of MII oocytes | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Number of Metaphase II Oocytes | 8.8 ± 6.7 | 1.0 ± 0 |
An oocyte was defined as fertilized if it had 2 pronuclei (2PN) at 19h (±2h).
| oocytes (number of fertilized oocytes) | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Number of Fertilized Oocytes | 6.4 ± 5.7 | 0.0 ± 0.1 |
The fertilization rate was defined as the number of 2PN oocytes divided by the number of oocytes retrieved. Fertilization rate relative to oocytes retrieved has been reported.
| percentage of fertilized oocytes | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Fertilization Rate | 56.4 ± 23.3 | 100.0 ± 0 |
Number of blastocysts (total and good-quality) on Day 5 are presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.
| blastocysts | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Number of blastocysts on day 5 | 3.7 ± 4.0 | 0.0 ± 0.0 |
| Number of good-quality blastocysts on day 5 | 2.3 ± 3.0 | 0.0 ± 0.0 |
Mean endometrial thickness is reported.
| mm | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Endometrial Thickness on Stimulation Day 5 | 8.0 ± 2.1 | 6.2 ± 1.9 |
Mean endometrial thickness is reported.
| mm | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Endometrial Thickness at End-of-stimulation | 10.6 ± 2.5 | 7.8 ± 2.3 |
The distribution of participants with hypoechogenic, isoechogenic, or hyperechogenic endometrium is reported
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Hypoechogenic | 64.2 | 57.4 |
| Isoechogenic | 6.4 | 5.6 |
| Hyperechogenic | 28.7 | 33.3 |
| Not possible to evaluate | 0.8 | 3.7 |
The distribution of participants with hypoechogenic, isoechogenic, or hyperechogenic endometrium is reported.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Hypoechogenic | 68.0 | 68.5 |
| Isoechogenic | 3.2 | 3.7 |
| Hyperechogenic | 28.4 | 25.9 |
| Not possible to evaluate | 0.4 | 1.9 |
Defined as the number of blastocysts transferred or cryopreserved divided by the number of oocytes retrieved. Data in this endpoint are presented for the cryopreserved cycles.
| blastocysts/oocyte retrieved | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Oocyte Utilization Rate | 30.6 ± 21.2 | 0.0 ± 0 |
Defined as the cumulative number of ongoing pregnancies per oocyte retrieved. Data in this endpoint are presented for the cryopreserved cycles. The unit of measure for this endpoint is 'cumulative ongoing pregnancies/oocyte retrieved'.
| ongoing pregnancies/oocyte retrieved | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Oocyte Efficiency Index | 4.5 ± 6.4 | 0.0 ± 0 |
Data in this endpoint are presented for the cryopreserved cycles. The unit is number of blastocysts with observations. One participant can contribute with a range from zero to multiple blastocysts.
| percentage of blastocysts | FE 999049 (Follitropin Delta) |
|---|---|
| Percentage of Blastocysts Surviving Cryopreservation | 98.5 |
Data in this endpoint are presented for the cryopreserved cycles. The unit is number of blastocysts with observations. One participant can contribute with a range from zero to multiple blastocysts.
| percentage of blastocysts | FE 999049 (Follitropin Delta) |
|---|---|
| Percentage of Blastocysts With Re-expansion After Cryopreservation | 97.2 |
The total number of cryopreserved cycles initiated are reported. Data in this endpoint are presented for the cryopreserved cycles. One participant can contribute with a range from zero to multiple blastocysts.
| Percentages of cycles | FE 999049 (Follitropin Delta) |
|---|---|
| Programmed cycles initiated | 92.1 |
| Natural cycles initiated | 7.9 |
The total number of cryopreserved cycles with blastocyst transfer are reported. Data in this endpoint are presented for the cryopreserved cycles. One participant can contribute with a range from zero to multiple blastocysts.
| Percentages of cycles | FE 999049 (Follitropin Delta) |
|---|---|
| Programmed cycles with transfer | 92.8 |
| Natural cycles with transfer | 7.2 |
Blood samples for analysis of circulating concentrations of AMH were drawn. The median and inter-quartile range (IQR) of AMH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
| pmol/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Stimulation day 1 | 13.2 (7.2 to 20.9) | 11.3 (6.7 to 18.3) |
| Stimulation day 5 | 10.9 (5.6 to 17.5) | 13.1 (6.6 to 19.6) |
| End-of-stimulation visit | 6.4 (3.6 to 10.5) | 14.6 (7.0 to 21.5) |
| Oocyte retrieval visit | 5.0 (2.9 to 8.0) | — |
Blood samples for analysis of circulating concentrations of FSH were drawn. The median and IQR of FSH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
| IU/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Stimulation day 1 | 8.7 (7.4 to 10.6) | 8.9 (7.4 to 10.5) |
| Stimulation day 5 | 20.5 (16.3 to 24.8) | 7.8 (6.3 to 9.4) |
| End-of-stimulation visit | 24.8 (20.2 to 30.3) | 7.1 (6.2 to 9.6) |
| Oocyte retrieval visit | 14.8 (12.4 to 17.8) | 20.2 (20.2 to 20.2) |
Blood samples for analysis of circulating concentrations of LH were drawn. The median and IQR of LH levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
| IU/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Stimulation day 1 | 4.8 (3.7 to 6.3) | 5.0 (3.6 to 6.6) |
| Stimulation day 5 | 2.4 (1.6 to 3.7) | 5.7 (4.3 to 7.3) |
| End-of-stimulation visit | 2.0 (1.3 to 3.3) | 8.8 (6.5 to 14.7) |
| Oocyte retrieval visit | 2.2 (1.2 to 3.7) | 28.1 (28.1 to 28.1) |
Blood samples for analysis of circulating concentrations of estradiol were drawn. The median and IQR of estradiol levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
| pg/mL | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Stimulation day 1 | 41.2 (33.7 to 52.6) | 40.2 (34.0 to 48.9) |
| Stimulation day 5 | 383.6 (235.1 to 599.6) | 59.0 (45.4 to 89.4) |
| End-of-stimulation visit | 1471.0 (891.0 to 2292.5) | 109.6 (52.0 to 174.6) |
| Oocyte retrieval visit | 745.1 (439.4 to 1177.3) | 107.4 (107.4 to 107.4) |
Blood samples for analysis of circulating concentrations of progesterone were drawn. The median and IQR of progesterone levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
| ng/mL | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Stimulation day 1 | 0.5 (0.3 to 0.7) | 0.5 (0.3 to 0.7) |
| Stimulation day 5 | 0.6 (0.3 to 0.8) | 0.3 (0.3 to 0.5) |
| End-of-stimulation visit | 1.1 (0.7 to 1.5) | 0.3 (0.3 to 0.6) |
| Oocyte retrieval visit | 6.2 (4.3 to 8.9) | 2.0 (2.0 to 2.0) |
Blood samples for analysis of circulating concentrations of inhibin A were drawn. The median and IQR of inhibin A levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
| pg/mL | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Stimulation day 1 | 5.3 (3.8 to 7.0) | 5.8 (4.3 to 7.0) |
| Stimulation day 5 | 70.3 (42.2 to 103.2) | 8.7 (6.0 to 12.1) |
| End-of-stimulation visit | 258.7 (159.6 to 379.8) | 19.8 (8.0 to 35.4) |
| Oocyte retrieval visit | 204.3 (136.9 to 287.1) | — |
Blood samples for analysis of circulating concentrations of inhibin B were drawn. The median and IQR of inhibin B levels on stimulation day 1, stimulation day 5, end-of-stimulation visit and oocyte retrieval visit are presented.
| pg/mL | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Stimulation day 1 | 75.0 (52.0 to 99.0) | 79.0 (51.0 to 99.0) |
| Stimulation day 5 | 517.0 (301.0 to 828.0) | 93.5 (77.0 to 112.0) |
| End-of-stimulation visit | 671.0 (356.0 to 1039.0) | 64.5 (51.0 to 97.0) |
| Oocyte retrieval visit | 301.5 (173.0 to 463.0) | — |
Calculated by start dates, end dates and daily dose of IMP.
| microgram of dose | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Total Gonadotropin Dose | 131.2 ± 30.8 | 146.5 ± 20.4 |
Calculated by start dates and end dates.
| days | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Number of Stimulation Days | 8.2 ± 1.4 | 8.5 ± 0.9 |
Investigator-requested decreases and increases of the gonadotropin dose.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Decrease | 6.2 | 0 |
| No change | 50.7 | 13.0 |
| Increase | 43.2 | 87.0 |
Any AE occurring after start of IMP and before the end-of-trial visit, or a pre-treatment AE or pre-existing medical condition that worsens in intensity after start of IMP and before the end-of-trial visit was considered treatment-emergent, and is presented for this endpoint. Data in this endpoint are presented for the fresh cycle.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 49.9 | 13.0 |
The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activity; moderate = event sufficient to affect usual activity (disturbing); or severe = inability to work or perform usual activities (unacceptable). Data in this endpoint are presented for the fresh cycle.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Mild AEs | 44.5 | 11.1 |
| Moderate AEs | 15.4 | 5.6 |
| Severe AEs | 0.9 | 0 |
Blood samples were collected for the analysis of clinical chemistry parameters including: Albumin and protein. Data in this endpoint are presented for the fresh cycle.
| g/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Albumin (End-of-stimulation visit) | -1.53 ± 2.45 | 0.18 ± 2.12 |
| Albumin (End-of-cycle visit) | -1.90 ± 2.75 | -0.65 ± 2.29 |
| Protein (End-of-stimulation visit) | -2.76 ± 3.98 | -0.17 ± 3.45 |
| Protein (End-of-cycle visit) | -1.92 ± 4.12 | -0.96 ± 3.55 |
Blood samples were collected for the analysis of clinical chemistry parameters including: Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase and gamma glutamyl transferase. Data in this endpoint are presented for the fresh cycle.
| IU/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Alanine aminotransferase (End-of-stimulation visit) | 0.3 ± 10.4 | 2.3 ± 18.9 |
| Alanine aminotransferase (End-of-cycle visit) | -0.7 ± 9.0 | -2.3 ± 18.0 |
| Alkaline phosphatase (End-of-stimulation visit) | -1.3 ± 7.2 | 1.6 ± 6.2 |
| Alkaline phosphatase (End-of-cycle visit) | -0.6 ± 9.6 | -0.9 ± 6.7 |
| Aspartate aminotransferase (Endof-stimulation visit) | 0.2 ± 8.6 | 2.0 ± 8.6 |
| Aspartate aminotransferase (End-of- cycle visit) | -0.9 ± 6.2 | -0.5 ± 6.4 |
| Gamma glutamy transferase (End-of-stimulation visit) | -1.5 ± 8.3 | -0.6 ± 6.5 |
| Gamma glutamyl transferase (End-of-cycle visit) | -1.0 ± 11.8 | -1.0 ± 8.2 |
Blood samples were collected for the analysis of clinical chemistry parameters including: Bicarbonate, blood urea nitrogen, calcium, chloride, cholesterol, glucose, Phosphate, Potassium and Sodium. Data in this endpoint are presented for the fresh cycle.
| mmol/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Bicarbonate (End-of-stimulation visit) | -0.05 ± 2.24 | 0.56 ± 2.22 |
| Bicarbonate (End-of-cycle visit) | -0.91 ± 2.42 | -0.47 ± 2.38 |
| Blood urea nitrogen (End-of-stimulation visit) | -0.2 ± 1.1 | -0.1 ± 1.1 |
| Blood urea nitrogen (End-of-cycle visit) | -0.3 ± 1.1 | 0.0 ± 1.1 |
| Calcium (End-of-stimulation visit) | -0.02 ± 0.08 | 0.02 ± 0.09 |
| Calcium (End-of-cycle visit) | -0.02 ± 0.09 | -0.01 ± 0.09 |
| Chloride (End-of-stimulation visit) | -0.6 ± 2.3 | 0.3 ± 2.1 |
| Chloride (End-of-cycle visit) | 0.4 ± 2.4 | 0.9 ± 2.3 |
| Cholesterol (End-of-stimulation visit) | -0.4 ± 0.5 | 0.0 ± 0.5 |
| Cholesterol (End-of-cycle visit) | 0.1 ± 0.6 | -0.1 ± 0.6 |
| Glucose (End-of-stimulation visit) | -0.1 ± 0.9 | 0.2 ± 0.9 |
| Glucose (End-of-cycle visit) | 0.0 ± 0.9 | 0.2 ± 1.1 |
| Phosphate (End-of stimulation visit) | -0.04 ± 0.16 | 0.03 ± 0.13 |
| Phosphate (End-of-cycle visit) | 0.01 ± 0.18 | 0.00 ± 0.18 |
| Potassium (End-of-stimulation visit) | 0.00 ± 0.44 | 0.19 ± 0.40 |
| Potassium (End-of-cycle visit) | 0.09 ± 0.47 | 0.25 ± 0.46 |
| Sodium (End-of-stimulation visit) | -0.6 ± 2.4 | 0.9 ± 2.5 |
| Sodium (End-of-cycle visit) | -0.4 ± 2.8 | 0.5 ± 2.5 |
Blood samples were collected for the analysis of clinical chemistry parameters including: Direct bilirubin, total bilirubin, creatinine, urate. Data in this endpoint are presented for the fresh cycle.
| umol/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Direct bilirubin (End-of-stimulation visit) | -0.09 ± 0.94 | -0.26 ± 0.82 |
| Direct bilirubin (End-of-cycle visit) | -0.28 ± 0.96 | -0.08 ± 0.92 |
| Total bilirubin (End-of-stimulation visit) | -0.58 ± 3.50 | -0.56 ± 3.92 |
| Total bilirubin (End-of-cycle visit) | -0.99 ± 3.64 | 0.23 ± 3.82 |
| Creatinine (End-of-stimulation visit) | -3.99 ± 7.48 | -0.18 ± 8.65 |
| Creatinine (End-of-cycle visit) | -3.47 ± 9.55 | 0.85 ± 7.27 |
| Urate (End-of-stimulation visit) | -1.13 ± 36.24 | -5.08 ± 36.99 |
| Urate (End-of-cycle visit) | -10.53 ± 48.58 | 6.06 ± 42.05 |
Blood samples were collected for the analysis of clinical chemistry parameters including: Lactate dehydrogenase. Data in this endpoint are presented for the fresh cycle.
| U/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| End-of-stimulation visit | -12.0 ± 18.5 | -3.8 ± 14.3 |
| End-of-cycle visit | -0.4 ± 20.7 | -0.8 ± 16.8 |
Blood samples were collected for the analysis of haematology parameter including: Erythrocytes. Data in this endpoint are presented for the fresh cycle.
| 10^12 cells/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| End-of-stimulation visit | -0.13 ± 0.23 | -0.03 ± 0.23 |
| End-of-cycle visit | -0.15 ± 0.26 | -0.07 ± 0.23 |
Blood samples were collected for the analysis of haematology parameters including: Haemoglobin. Data in this endpoint are presented for the fresh cycle.
| g/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| End-of-stimulation visit | -3.75 ± 6.60 | -0.20 ± 6.86 |
| End-of-cycle visit | -3.94 ± 7.64 | -1.76 ± 6.86 |
Blood samples were collected for the analysis of haematology parameter including: Haematocrit. Data in this endpoint are presented for the fresh cycle.
| ratio | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| End-of-stimulation visit | 0.0 ± 0.0 | 0.0 ± 0.0 |
| End-of-cycle visit | 0.0 ± 0.0 | 0.0 ± 0.0 |
Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular volume. Data in this endpoint are presented for the fresh cycle.
| fL | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| End-of-stimulation visit | 1.4 ± 3.0 | 1.2 ± 3.2 |
| End-of-cycle visit | 1.1 ± 3.1 | 1.4 ± 3.0 |
Blood samples were collected for the analysis of haematology parameters including: Leukocytes and platelets. Data in this endpoint are presented for the fresh cycle.
| 10^9 cells/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Leukocytes (End-of-stimulation visit) | 0.904 ± 1.913 | -0.822 ± 1.508 |
| Leukocytes (End-of-cycle visit) | 0.357 ± 2.174 | -0.534 ± 1.636 |
| Platelets (End-of-stimulation visit) | -3.0 ± 41.0 | -2.0 ± 35.1 |
| Platelets (End-of-cycle visit) | 9.5 ± 50.2 | -16.1 ± 42.1 |
Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular haemoglobin. Data in this endpoint are presented for the fresh cycle.
| picogram | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| End-of-stimulation visit | 0.1 ± 0.8 | 0.1 ± 1.0 |
| End-of-cycle visit | 0.1 ± 0.9 | 0.1 ± 0.8 |
Blood samples were collected for the analysis of haematology parameter including: Erythrocyte mean corpuscular haemoglobin concentration. Data in this endpoint are presented for the fresh cycle.
| mmol/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| End-of-stimulation visit | -0.3 ± 0.8 | -0.2 ± 0.8 |
| End-of-cycle visit | -0.2 ± 0.8 | -0.3 ± 0.7 |
Blood samples were collected for the analysis of haematology parameters including: Basophils/leukocytes, eosinophils/ leukocytes, lymphocytes/leukocytes, monocytes/leukocytes and neutrophils/leukocytes. Data in this endpoint are presented for the fresh cycle.
| percentage | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Basophils/leukocytes (End-of-stimulation visit) | 0.11 ± 0.52 | 0.10 ± 0.62 |
| Basophils/leukocytes (End-of-cycle visit) | 0.07 ± 0.43 | 0.01 ± 0.55 |
| Eosinophils/leukocytes (End-of-stimulation visit) | -0.36 ± 1.25 | 0.03 ± 1.16 |
| Eosinophils/leukocytes (End-of-cycle visit) | -0.16 ± 1.35 | 0.04 ± 0.99 |
| Lymphocytes/leukocytes (End-of-stimulation visit) | -5.46 ± 6.73 | 0.59 ± 6.34 |
| Lymphocytes/leukocytes (End-of-cycle visit) | -1.27 ± 8.24 | 0.80 ± 5.39 |
| Monocytes/leukocytes (End-of-stimulation visit) | -0.44 ± 1.73 | 0.00 ± 1.74 |
| Monocytes/leukocytes (End-of-cycle visit) | 0.14 ± 1.73 | 0.66 ± 1.80 |
| Neutrophils/leukocytes (End-of-stimulation visit) | 6.14 ± 7.67 | -0.73 ± 7.40 |
| Neutrophils/leukocytes (End-of-cycle visit) | 1.22 ± 9.09 | -1.51 ± 6.27 |
The table represents the percentage of participants in each group with normal baseline values and markedly abnormal end-of-stimulation or end-of-cycle visit values for alanine aminotransferase, aspartate aminotransferase, bicarbonate, calcium, potassium. Data in this endpoint are presented for the fresh cycle.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Alanine aminotransferase (End-of-stimulation visit) | 0.2 | 0.0 |
| Aspartate aminotransferase (End-of-stimulation visit) | 0.2 | 0.0 |
| Bicarbonate (End-of-stimulation visit) | 0.2 | 0.0 |
| Calcium (End-of-stimulation visit) | 0.0 | 2.1 |
| Glucose (End-of-stimulation visit) | 0.3 | 0.0 |
| Potassium (End-of-stimulation visit) | 0.2 | 0.0 |
| Alanine aminotransferase (End-of-cycle visit) | 0.2 | 0.0 |
| Bicarbonate (End-of-cycle visit) | 0.2 | 0.0 |
The table represents the percentage of participants in each group with normal baseline values and markedly abnormal end-of-stimulation or end-of-cycle visit values for Leukocytes, eosinophils/leukocytes, lymphocytes/leukocytes and neutrophils/leukocytes. Data in this endpoint are presented for the fresh cycle.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Leukocytes (End-of-stimulation visit) | 0.2 | 0.0 |
| Eosinophils/leukocytes (End-of-stimulation visit) | 0.2 | 0.0 |
| Lymphocytes/leukocytes (End-of-stimulation visit) | 0.4 | 0.0 |
| Neutrophils/leukocytes (End-of-stimulation visit) | 0.2 | 0.0 |
| Leukocytes (End-of-cycle visit) | 0.6 | 0.0 |
| Eosinophils/leukocytes (End-of-cycle visit) | 0.2 | 0.0 |
Assessed by the participant during the stimulation period. Participants assessed the injection site reactions (redness, pain, itching, swelling and bruising) three times daily: immediately after the injection, 30 minutes after the injection and 24 hours after the injection.
| percentage of events | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Frequency and Intensity of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period | 4.2 | 4.0 |
Assessed by the participant during the stimulation period as mild, moderate or severe.
| percentage of events | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Mild injection site reaction | 4.0 | 3.9 |
| Moderate injection site reaction | 0.1 | 0.1 |
| Severe injection site reaction | 0.0123 | 0.0147 |
Measured by presence of anti-FSH antibodies. 95% Clopper-Pearson confidence interval has been reported in this endpoint.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Treatment-induced anti-FSH antibodies (Overall) | 0.75 (0.20 to 1.91) | 0.00 (0.00 to 6.60) |
| Treatment-induced anti-FSH antibodies with neutralizing capacity | 0 (NA to NA) | 0 (NA to NA) |
Standardised Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs).
| events | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| SMQ = Severe cutaneous adverse reactions | 3 | 0 |
| SMQ = Anaphylactic reaction | 7 | 1 |
| SMQ = Angioedema | 2 | 0 |
| SMQ = Hypersensitivity | 13 | 1 |
| Any general and local hypersensitivity reactions | 11 | 1 |
For each participant the reason for cycle cancellation will be recorded. Data in this endpoint are presented for the fresh cycle.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| AE (including immune-related AEs) | 0 | 0 |
| Technical malfunctions of the administration pen | 0 | 0 |
Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe. Data in this endpoint are presented for the fresh cycle.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| OHSS (any grade) | 2.4 | 0 |
| OHSS (moderate/severe) | 1.5 | 0 |
Percentage of participants hospitalized or undergoing paracentesis due to OHSS are reported
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Hospitalization | 0 | 0 |
| Paracentesis | 0 | 0 |
Defined as pregnancy with more than one fetus. Among participants with ongoing pregnancy, percentage of participants with twin pregnancies are presented. '%' in the unit of measure refers to 'percentage'.
| % of participants with twin pregnancy | FE 999049 (Follitropin Delta) |
|---|---|
| Proportion of Participants With Multi-fetal Gestation in the Fresh Cycle | 2.6 |
Defined as pregnancy with more than one fetus. Among cryopreserved cycles with ongoing pregnancy, percentage of cycles with twin pregnancies are presented. '%' in the unit of measure refers to 'percentage'.
| % of cycles with twin pregnancy | FE 999049 (Follitropin Delta) |
|---|---|
| Proportion of Cryopreserved Cycles With Multi-fetal Gestation | 3.4 |
The percentage of participants with biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins in the fresh cycle are presented. Data represents participants with positive βhCG. Data is not shown for placebo arm because no participants had a positive βhCG. '%' in the unit of measure refers to 'percentage'. Unit: % of participants with early pregnancy loss.
| % of participants | FE 999049 (Follitropin Delta) |
|---|---|
| Biochemical pregnancy | 15.8 |
| Spontaneous abortion | 15.2 |
| Induced abortion | 0.0 |
| Ectopic pregnancy | 0.6 |
The percentage of cryopreserved cycles with biochemical pregnancy, spontaneous abortion, ectopic pregnancy (with and without medical/surgical intervention) and vanishing twins are presented. Data is not shown for placebo arm because no participants had a positive βhCG. '%' in the unit of measure refers to 'percentage'.
| % of cycles with early pregnancy loss | FE 999049 (Follitropin Delta) |
|---|---|
| Biochemical pregnancy | 16.8 |
| Spontaneous abortion | 18.9 |
| Induced abortion | 0.0 |
| Ectopic pregnancy | 1.1 |
Incidences of technical malfunctions of the administration pen were recorded.
| percentage of participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Proportion of Participants With Technical Malfunctions of the Administration Pen | 0 | 0 |
Collected over The AEs were recorded from time of signing informed consent to end-of-trial (up to Ongoing pregnancy visit (10-11 weeks after transfer)). Data for the AEs is presented for the fresh cycle and cryopreserved cycle.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FE 999049 (Follitropin Delta) | 0/533 (0%) | 2/533 (0.4%) | 151/533 (28.3%) |
| Placebo | 0/54 (0%) | 0/54 (0%) | 2/54 (3.7%) |
| Event | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/533 | 0/54 |
| Hyperemesis gravidarumPregnancy, puerperium and perinatal conditions | 1/533 | 0/54 |
| Event | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 111/533 | 0/54 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 32/245 | 0/54 |
| Biochemical pregnancy (Cryopreserved cycle)Pregnancy, puerperium and perinatal conditions | 29/245 | 0/54 |
| Morning sicknessPregnancy, puerperium and perinatal conditions | 27/245 | 0/54 |
| HeadacheNervous system disorders | 29/533 | 2/54 |
| Biochemical pregnancy (Fresh cycle)Pregnancy, puerperium and perinatal conditions | 27/533 | 0/54 |
The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment.
| Age, Continuous(years) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| Mean | 37.7 ± 2.1 | 37.9 ± 2.1 | 37.7 ± 2.1 |
| Sex: Female, Male(Participants) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| Female | 533 | 54 | 587 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 57 | 9 | 66 |
| Not Hispanic or Latino | 476 | 45 | 521 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 57 | 5 | 62 |
| Native Hawaiian or Other Pacific Islander | 5 | 0 | 5 |
| Black or African American | 70 | 4 | 74 |
| White | 398 | 45 | 443 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Body mass index (BMI)(kg/m^2) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| Mean | 27.0 ± 5.1 | 27.9 ± 5.1 | 27.0 ± 5.1 |
| Primary infertility(participants) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| Number | 226 | 26 | 252 |
| Duration of infertility(months) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| Mean | 42.7 ± 37.6 | 45.9 ± 43.2 | 43.0 ± 38.1 |
| Primary reason for infertility(Participants) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| Unexplained infertility | 251 | 28 | 279 |
| Tubal infertility | 120 | 7 | 127 |
| Mild male factor | 50 | 5 | 55 |
| Moderate male factor | 62 | 8 | 70 |
| Severe male factor | 27 | 4 | 31 |
| Endometriosis stage I/II | 20 | 2 | 22 |
| Endometriosis stage III/IV | 1 | 0 | 1 |
| Other | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Dec 2020, 25 months.
Results were first posted in Jan 2024, 3 years after primary completion. A results delay was requested in Nov 2021.
Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 25 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta